{"id":438479,"date":"2025-02-05T00:00:00","date_gmt":"2025-02-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0023-2025-biopharma-alzheimers-disease-unmet-need-unmet-need-early-alzheimers-disease-us-eu\/"},"modified":"2026-04-14T10:13:17","modified_gmt":"2026-04-14T10:13:17","slug":"unnecg0023-2025-biopharma-alzheimers-disease-unmet-need-unmet-need-early-alzheimers-disease-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0023-2025-biopharma-alzheimers-disease-unmet-need-unmet-need-early-alzheimers-disease-us-eu\/","title":{"rendered":"Alzheimer&#8217;s Disease &#8211; Unmet Need &#8211; Unmet Need &#8211; Early Alzheimer&#8217;s Disease (US\/EU)"},"content":{"rendered":"<p>Eisai \/ Biogen\u2019s lecanemab (Leqembi) and Eli Lilly\u2019s donanemab (Kisunla) are modestly effective in reducing cognitive and functional decline, require frequent <abbr title=\"intravenous\">IV<\/abbr> infusions, and carry <abbr title=\"amyloid-related imaging abnormalities\">ARIA<\/abbr>-related safety risks. Emerging <abbr title=\"disease-modifying therapy\">DMT<\/abbr>s with near-term launch potential (e.g., subcutaneous lecanemab, Eli Lilly\u2019s remternetug, Roche\u2019s trontinemab, Novo Nordisk\u2019s semaglutide) may deliver greater biomarker and\/or clinical efficacy, lower <abbr title=\"amyloid-related imaging abnormalities\">ARIA<\/abbr> risk, or improved delivery profiles. This report examines the influence of a key clinical (e.g., reduction of cognitive and functional decline, plaque clearance, <abbr title=\"amyloid-related imaging abnormalities\">ARIA<\/abbr> risk) and nonclinical (i.e., out-of-pocket cost) attributes on neurologists\u2019 prescribing decisions and assesses the key opportunities for differentiation from Leqembi, Kisunla, and procognitive symptomatics in the early <abbr title=\"Alzheimer's disease\">AD<\/abbr> market.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"BulletListStyle1 SCXW125561952 BCX8 round-bullets\">\n<li>How important is a therapy\u2019s effect on cognition, function, or biomarker outcomes in neurologists\u2019 selection of a therapy for early <abbr title=\"Alzheimer's disease\">AD<\/abbr>?<\/li>\n<li>How do neurologists rate Leqembi, Kisunla, and procognitive symptomatics on their overall performance in the treatment of early <abbr title=\"Alzheimer's disease\">AD<\/abbr> and on key individual attributes?<\/li>\n<li>Based on conjoint analysis and <abbr title=\"Target Product Profile\">TPP<\/abbr> simulation, what trade-offs among efficacy, safety, treatment duration, and other factors are neurologists willing to make when considering a hypothetical <abbr title=\"disease-modifying therapy\">DMT<\/abbr> for early <abbr title=\"Alzheimer's disease\">AD<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW125561952 BCX8 round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 61 U.S. and 32 European neurologists fielded in December 2023<\/p>\n<p><strong>Key companies:<\/strong>\u00a0AbbVie, Biogen, Eisai, Eli Lilly, Roche<\/p>\n<p><strong>Key drugs:<\/strong>\u00a0Leqembi, Kisunla, donepezil, galantamine, Namzaric, rivastigmine patch<\/p>\n","protected":false},"template":"","class_list":["post-438479","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-alzheimers-disease","biopharma-therapy-areas-neurology","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/438479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/438479\/revisions"}],"predecessor-version":[{"id":438831,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/438479\/revisions\/438831"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=438479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}